PHILADELPHIA, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments, announced today that members of company management and a principal investigator will participate in the following American Association of Ophthalmology (AAO) Annual Meeting events between Oct. 13 and Oct. 18:
2016 Ophthalmology Innovation Summit, or OIS@AAO, at the Hyatt Regency Chicago
- Jeffrey D. Marrazzo, chief executive officer, will participate in the Gene Therapy Breakfast Break-Out Panel discussion on Thursday, Oct. 13, at 7:30 a.m. (CDT)
Retina Days Subspecialty Meeting, at the McCormick Center in Chicago
- Albert M. Maguire, M.D., professor of ophthalmology at the Perelman School of Medicine of the University of Pennsylvania, will talk about “Gene Therapy for Leber Amaurosis Type 2 – Clinical Trials Results,” including data from the pivotal Phase 3 trial of voretigene neparvovec on Friday, Oct. 14, at 12:13 p.m. (CDT)
Additionally, the company will have a booth presence in the McCormick Center exhibit hall throughout the AAO meeting. Visit us at Booth 1980.
About Spark Therapeutics Spark Therapeutics, a fully integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments. Spark Therapeutics’ validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases, liver-associated diseases, such as hemophilia, and neurodegenerative diseases. Spark Therapeutics’ validated platform has successfully delivered proof-of-concept data with investigational gene therapies in the eye and liver. Spark Therapeutics’ most advanced product candidate, voretigene neparvovec (formerly referred to as SPK-RPE65 ), which has received both breakthrough therapy and orphan product designations, has reported top-line results from a pivotal Phase 3 clinical trial for the potential treatment of a rare blinding condition. Spark Therapeutics’ hemophilia franchise has two lead assets: SPK-9001 in a Phase 1/2 trial for hemophilia B and SPK-8011 , a preclinical candidate for hemophilia A. To learn more, please visit www.sparktx.com .
Spark Therapeutics Corporate Contacts Stephen W. Webster, Chief Financial Officer Daniel Faga, Chief Business Officer (855) SPARKTX (1-855-772-7589) Media Contact Dan Quinn Ten Bridge Communications (781) 475-7974 dan@tenbridgecommunications.com
